Table 3 Frequencies according to EMA guidelines for 1st line ICI therapy of urothelial cancers
From: Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Scores | 28–8 | 22c3 | SP263 | SP142 | 28–8 | 22c3 | SP263 | SP142 |
|---|---|---|---|---|---|---|---|---|
IC ≥ 5%a | (17/63) 27% | (11/61) 18% | (18/63) 29% | (1/63) 2% | (10/43) 23% | (7/44) 16% | (14/43) 33% | (1/45) 2% |
CPS ≥ 10b | (13/63) 21% | (12/61) 20% | (20/63) 32% | (1/63) 2% | (10/43) 23% | (3/44) 7% | (20/43) 47% | (1/45) 2% |